The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation

Anti-β2-glycoprotein I antibodies

(2013) Rohan Willis et al.   Annals of the New York Academy of Sciences

B cells are critical for autoimmune pathology in Scurfy mice

(2013) S. Aschermann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The significance of autoantibodies against  2-glycoprotein I

(2012) P. G. de Groot et al.   BLOOD

Infections and vaccines in the etiology of antiphospholipid syndrome

(2012) Paola Cruz-Tapias et al.   CURRENT OPINION IN RHEUMATOLOGY

Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome

(2012) Paul Seed et al.   THROMBOSIS AND HAEMOSTASIS

Anti- 2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?

(2010) L. Andreoli et al.   ANNALS OF THE RHEUMATIC DISEASES

The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo

(2010) Robert M Anthony et al.   Current Opinion in Organ Transplantation

A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs

(2010) Robert M. Anthony et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Generation of a C3c specific monoclonal antibody and assessment of C3c as a putative inflammatory marker derived from complement factor C3

(2010) Yaseelan Palarasah et al.   JOURNAL OF IMMUNOLOGICAL METHODS

IgG glycosylation analysis

(2009) Carolin Huhn et al.   PROTEOMICS

Complement activation in patients with primary antiphospholipid syndrome

(2008) K Oku et al.   ANNALS OF THE RHEUMATIC DISEASES

Infections and the Antiphospholipid Syndrome

(2008) Mario García-Carrasco et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Antiphospholipid syndrome in children

(2008) Tadej Avčin   CURRENT OPINION IN RHEUMATOLOGY

Glycosylation of Recombinant Antibody Therapeutics

(2005) Royston Jefferis   BIOTECHNOLOGY PROGRESS